PECAM1 and cancer: Based on the results of the comparative analysis between cancer patients and healthy volunteers, we focused on a possible correlation between total, CD31 +, or CD133 + CD326− EV concentrations and the overall survival of the total cancer patient cohort or of the cancer subgroups (Figure 2).